epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.
EPI-118, Phase II. In start-up
Treatment-resistant major depressive disorder
FBK-118 against placebo in treatment-resistant major depressive disorder. Sponsor: Fabrikam Neuroscience (fictional), CNS and psychiatry.
When will this study finish recruiting? Set its sites yourself, or let the planner find the fewest per country that meet the deadline.
Study and plan
Fabrikam Neuroscience (fictional), Phase II, CNS and psychiatry. Month 0 is May 2026.
Randomise 243 (drop-out 26%) and screen about 566 (screen failure 57%)
May 2029
Confidence wanted
Sites per countryEdit the site counts in the table below
How much sites differSpread of site rates (coefficient of variation 0.9). Fitted trials range from 0.7 to 1.2.
Central finish (P50)Feb 2029month 33.3
Fast case (P10)Aug 2028month 27.9
Slow case (P90)Sep 2029month 41.0
Chance of meeting the deadline69%wanted 85%
Sites13533% likely to recruit nobody
Patients to screen566to randomise 243
On course to finish in February 2029, three months before the deadline
EPI-118, patients randomised, cumulative by monthThe band holds 80% of 4,000 simulated studies; the coloured line is the central forecast; the line marked Actual is recruitment so far
Show data
Patients randomised by month: fast, central and slow cases of the simulation, and actual recruitment
Month
Fast case
Central
Slow case
Actual
May 2026
0
0
0
0
Aug 2026
0
0
0
0
Nov 2026
0
0
0
–
Feb 2027
9
5
2
–
May 2027
29
20
12
–
Aug 2027
60
43
29
–
Nov 2027
99
73
52
–
Feb 2028
142
106
77
–
May 2028
186
139
102
–
Aug 2028
229
172
127
–
Nov 2028
243
205
152
–
Feb 2029
243
239
177
–
May 2029
243
243
202
–
Aug 2029
243
243
227
–
Nov 2029
243
243
243
–
Feb 2030
243
243
243
–
May 2030
243
243
243
–
Source: epiClinical Poisson-gamma simulation; actual recruitment to September 30th 2026. All data synthetic.
How likely is it to finish by a given month?
About a two-in-three chance of finishing by May 2029
Finish month of 4,000 simulated studiesOne dot = 40 simulated studies · 69 of 100 dots finish in time
Drag the handle or
In time: 69%Median Feb 2029Late: 31%
Source: epiClinical Poisson-gamma simulation
Show data
Chance that recruitment is complete by the end of each month
Month
Chance complete by then
May 2026
0%
Aug 2026
0%
Nov 2026
0%
Feb 2027
0%
May 2027
0%
Aug 2027
0%
Nov 2027
0%
Feb 2028
0%
May 2028
0%
Aug 2028
6%
Nov 2028
23%
Feb 2029
47%
May 2029
69%
Aug 2029
83%
Nov 2029
92%
Feb 2030
96%
May 2030
98%
Countries
Use
Country
Patients per site per month
Sites open between
Cap
Sites
Patients by finish
United States
0.067
Therapeutic area: 0.450 CNS and psychiatry baseline
Country: ×0.75 United States
Site type: ×1.009 Usual mix in United States, leaning to independent sites
Track record: ×0.865 Expected mix for mostly new sites
Protocol and population: ×0.55 Highly restrictive eligibility ×0.55
Patient acceptability: ×0.55 Placebo or no added treatment ×0.75, Blinded ×0.8, Heavier than typical ×0.8
Competing trials: ×0.75 Heavy competition ×0.75
month 5.8 to 11.9
100
97
United Kingdom
0.074
Therapeutic area: 0.450 CNS and psychiatry baseline
Country: ×0.85 United Kingdom
Site type: ×0.988 Usual mix in United Kingdom, leaning to independent sites
Track record: ×0.865 Expected mix for mostly new sites
Protocol and population: ×0.55 Highly restrictive eligibility ×0.55
Patient acceptability: ×0.55 Placebo or no added treatment ×0.75, Blinded ×0.8, Heavier than typical ×0.8
Competing trials: ×0.75 Heavy competition ×0.75
month 5.7 to 11.7
44
45
Spain
0.087
Therapeutic area: 0.450 CNS and psychiatry baseline
Country: ×1 Spain
Site type: ×0.98 Usual mix in Spain, leaning to independent sites
Track record: ×0.865 Expected mix for mostly new sites
Protocol and population: ×0.55 Highly restrictive eligibility ×0.55
Patient acceptability: ×0.55 Placebo or no added treatment ×0.75, Blinded ×0.8, Heavier than typical ×0.8
Competing trials: ×0.75 Heavy competition ×0.75
month 9.3 to 15.3
71
45
Poland
0.130
Therapeutic area: 0.450 CNS and psychiatry baseline
Country: ×1.4 Poland
Site type: ×1.052 Usual mix in Poland, leaning to independent sites
Track record: ×0.865 Expected mix for mostly new sites
Protocol and population: ×0.55 Highly restrictive eligibility ×0.55
Patient acceptability: ×0.55 Placebo or no added treatment ×0.75, Blinded ×0.8, Heavier than typical ×0.8
Competing trials: ×0.75 Heavy competition ×0.75
month 12.8 to 18.8
41
56
Country risks to weigh when choosing sites
United States
Two sourced risks
All sites
The first US site opens quickly, but the rest of the US sites open slowly.
The US activates its first site quickly but scales its site fleet slowly · PM-03 · grade B
Tightens: site activation overdue
All sites
Under-represented groups need a plan from the start; diversity action plans apply to Phase III studies.
Racial and ethnic under-representation · PB-12 · grade A
United Kingdom
Two sourced risks
Some sites
Costing and contracting were the longest start-up step; the national contract has shortened it.
Fragmented, negotiated costing and contracting · POL-03 · grade A
If it recurs
The regulator's backlog of 2023 was cleared, but could recur.
Regulator assessment backlog · POL-02 · grade A
Spain
Two sourced risks
All sites
Site contracts took 117 days in 2016 and about 90 after national templates.
Fragmented, negotiated costing and contracting · POL-03 · grade A
All sites
Applications go through the EU Clinical Trials Regulation and its portal.
Regional regulatory transition friction (EU CTR and CTIS) · POL-15 · grade A
Poland
Two sourced risks
All sites
Applications go through the EU Clinical Trials Regulation and its portal.
Regional regulatory transition friction (EU CTR and CTIS) · POL-15 · grade A
All sites
A central ethics committee reviews every study; its effect on timelines is not measured.
Ethics-committee structure (random CPP allocation, 40 Italian territorial committees, a central Polish committee, Denmark's timeliness) · POL-20 · grade B
Risk-register entries; the choice of entries per country is epiClinical's.